A Multi-Center, Open-Label, Randomized, Phase 2 Clinical Trial Evaluating Saftey and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-Type KRAS Tumors.

Trial Profile

A Multi-Center, Open-Label, Randomized, Phase 2 Clinical Trial Evaluating Saftey and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-Type KRAS Tumors.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Panitumumab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms SPIRITT
  • Sponsors Amgen
  • Most Recent Events

    • 04 Jun 2013 Status changed from active, no longer recruiting to completed, according to presentation of results.
    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top